Atalanta Therapeutics key facts
as of Oct 2026- Developer of targeted RNA-modulating therapeutics designed for the treatment of genetically defined diseases.
- Atalanta Therapeutics is valued at approximately $45.0M as of Oct 2026 (last reported valuation).
- It has raised $227.0M; the latest was Later Stage VC ($97.0M) in Jan 2025.
- Notable investors include F-Prime Capital, Mirae Asset Capital, EQT Life Sciences, Novartis Venture Fund, Pictet — 11 tracked in total.
- Status: Privately Held (backing).
Atalanta Therapeutics's last reported valuation, Jun 2018. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Atalanta Therapeutics: the Monday email on marks, rounds and moves
Atalanta Therapeutics funding rounds
No funding rounds for Atalanta Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Atalanta Therapeutics
11+Atalanta Therapeutics valuation
Atalanta Therapeutics's last reported valuation was $45 million in Jun 2018. No priced round, secondary trade or fund mark has surfaced since.
Atalanta Therapeutics investors
11 investors are on record for Atalanta Therapeutics, including F-Prime Capital, Mirae Asset Capital, EQT Life Sciences and Novartis Venture Fund.
About Atalanta Therapeutics
Developer of targeted RNA-modulating therapeutics designed for the treatment of genetically defined diseases. The company utilizes proprietary structure-switching molecules to modulate gene expression, including oncology, neurology, and rare genetic disorders, enabling the biopharmaceutical industries to address previously undruggable targets across multiple disease areas.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2018
- Employees
- 55
- Website
- atalantatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.